Month: August 2020

SAINT PAUL, Minn., , Aug. 12, 2020 (GLOBE NEWSWIRE) — Image Sensing Systems, Inc. (Nasdaq: ISNS) today announced results for its quarter and first half ended June 30, 2020.Second Quarter 2020 Financial SummarySecond quarter royalties remained consistent at $2.2 million when compared to the same period in the prior year.Second quarter product sales were $1.2 million, a decrease of 42 percent from the same period in the prior year.Operating expenses totaled $2.4 million in the second quarter of 2020, an increase of 1 percent from the prior year period.There were no capitalized software costs in the second quarter of 2020 compared to $343,000 in the prior year period.Net income for the second quarter of 2020 totaled $150,000 compared to net income of $647,000 for the same period in the prior year.The Company received funding of $924,000...

Vroom Delivers Ahead of Growth PlanEcommerce Unit Sales Up 74%NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) — Vroom, Inc. (NASDAQ:VRM), a leading e-commerce platform for buying and selling used vehicles, today announced financial results for the second quarter ended June 30, 2020 (“Q2 2020”).HIGHLIGHTS OF SECOND QUARTER 20206,713 Ecommerce units sold, 1,110 TDA units sold, 3,259 Wholesale units soldRevenue of $253.1 millionGross profit of $7.6 millionAdjusted EBITDA of $(39.0) million(a)Loss from operations of $(41.4) millionAdjusted loss from operations of $(40.1) million(a)Net loss of $(63.2) millionNon-GAAP net loss of $(40.7) million(a)Net loss per share of $(2.00)Non-GAAP net loss per share, as adjusted of $(0.34)(a)           (a) See section entitled “Non-GAAP Measures” for adjustment details and reconciliations of these non-GAAP...

MINNEAPOLIS, Aug. 12, 2020 (GLOBE NEWSWIRE) — BBQ Holdings, Inc. (NASDAQ: BBQ) (the “Company”), an innovating global owner and operator of restaurants, today reported financial results for the second fiscal quarter ended June 28, 2020.  Note: The second quarter results were affected by the COVID-19 pandemic as well as federal and state level mandates requiring restaurants to limit or eliminate in-store dining.Second Quarter 2020 Highlights:Company-owned Famous Dave’s second quarter same store net sales decreased 22.9% compared to second quarter 2019.Franchise-operated same store net sales decreased 31.5%.Same store to-go sales increased 106.0% at Company-owned Famous Dave’s restaurants.Granite City second quarter same store net sales decreased 65.5% compared to second quarter 2019, however, Granite City same store sales grew from...

Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, KakenBOULDER, Colo., Aug. 12, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.“We announced several milestones during the first half of 2020 that strengthened our ability to execute our strategy to develop sofpironium bromide as a treatment for primary axillary hyperhidrosis in the U.S. and in Japan. Most notable are the successful completion of our U.S. Phase 3 long-term safety study, the positive...

NL-201 IND submission anticipated during fourth quarter of 2020Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline development into 2023Company to host Conference Call Today, August 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. EasternSEATTLE, Aug. 12, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ending June 30, 2020 and a midyear corporate update.“All of the preclinical activities for NL-201 are substantially complete, and we are excited to be moving towards our first clinical trial in patients with advanced solid tumors,” said Jonathan Drachman, M.D., Chief Executive Officer...

BIRMINGHAM, Mich., Aug. 12, 2020 (GLOBE NEWSWIRE) — Conifer Holdings, Inc. (Nasdaq: CNFR) (“Conifer” or the “Company”) today announced results for the second quarter ended June 30, 2020.Second Quarter 2020 Financial Highlights (compared to the prior year period)Gross written premium increased 9.4% to $27.5 millionThe Company’s overall combined ratio was 100.5% (accident year combined ratio was 86.6%)Commercial lines represented approximately 93% of gross written premiumCommercial Lines combined ratio improved 6 percentage points to 101.7% (accident year combined ratio was 86.5%)Personal Lines combined ratio was 85.7% (accident year combined ratio was 86.9%)Net income of $1.5 million, or $0.16 per share, based on 9.6 million average shares outstandingBook value per share of $4.51 as of June 30, 2020, an improvement of 18.4% sequentially...

NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal first quarter ended June 30, 2020.  Immunovant ended the quarter with approximately $280.3 million in cash.    Financial Highlights for Fiscal First Quarter ended June 30, 2020:R&D Expenses: Research and development expenses decreased by $1.6 million, from $18.5 million for the three months ended June 30, 2019, to $16.9 million for the three months ended June 30, 2020. Note that research and development expense for the three months ended June 30, 2019 included $10.0 million related to the achievement in May 2019 of the first development and regulatory milestone under Immunovant’s license agreement...

MITCHEL FIELD, N.Y., Aug. 12, 2020 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) today announced the award of a contract for precision oscillators for end use on US military platforms. The oscillators are a key component of the communication systems for a variety of platforms and follow several previous contracts for similar high performance oscillators. The contract value is $5.0M. The contract period of performance is approximately two years.FEI CEO Stan Sloane commented, “We are extremely pleased to receive this award and continue to supply these key components for US military applications. FEI’s precision oscillators continue to be selected for their excellent performance in dynamic environments, their high reliability and our track record of delivering on time.”About Frequency ElectronicsFrequency...

— Companies to jointly validate novel drug targets —— Scipher eligible for upfront, opt-in and milestone payments —— Galapagos to progress selected targets into drug discovery —Mechelen, Belgium and Boston, USA; 12 August 2020 – Galapagos NV (Euronext & Nasdaq: GLPG) and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused on autoimmune diseases, today announce a collaboration to advance novel drug targets identified by Scipher for the treatment of inflammatory bowel disease (IBD).   Scipher combines its proprietary Network Medicine Platform with molecular patient data and AI-based methods to identify novel targets and pathways in autoimmune diseases, including IBD.Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by...